Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lutetium (177Lu) pocuvotide satetraxetan
- Development stage
- Unknown
- Lead developer
- Cellbion
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Peptides
- Administration
- Intravenous
01
Overview
Lutetium (177Lu) pocuvotide satetraxetan (also known as 177Lu-DGUL) is a novel prostate-specific membrane antigen (PSMA)-targeted radioligand therapy developed by Cellbion in collaboration with Seoul National University Hospital. It consists of a Glu-Urea-Lys derivative (DGUL) that binds with high affinity to PSMA, conjugated via a short hydrophilic thiourea-containing linker to the chelator satetraxetan, which coordinates the beta-emitting radionuclide lutetium-177 (177Lu). Upon binding to PSMA-expressing prostate cancer cells, the radioligand is internalized, delivering localized ionizing radiation that induces DNA damage and cell death. 177Lu-DGUL is being developed for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
- Other names
- lutetium Lu 177 pocuvotide satetraxetanlutetium Lu-177 pocuvotide satetraxetanpocuvotide satetraxetan
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on lutetium (177Lu) pocuvotide satetraxetan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lutetium (177Lu) pocuvotide satetraxetan.